Costs of HAIs | Xenex
Successfully combating HAIs has become a significant and actionable financial opportunity for U.S. hospitals today.
In January 2015, CMS began measuring C. difficile and MRSA infections as key performance standards in the Value Based Purchasing (VBP) and Hospital Acquired Condition (HAC) Reduction Programs. By 2017, 5% of hospital inpatient Medicare reimbursement will depend upon performance in these programs. Hospitals are now scored on items like patient satisfaction (HCAHPS) and their infection rate. These scores directly impact reimbursement, potentially costing millions of dollars.
Our customized pricing strategies recommend a specific number of Robots based on the number of beds within your facility, the number of daily discharges, current infection rates and any special areas of interest and concern. We also have financing options and leasing programs available.